Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Bone Neoplasms × ridaforolimus × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 4 Osteosarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 Liposarcoma 1 Leiomyosarcoma 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Bone Neoplasms 1

Interventions

Ibandronic Acid 8 Gemcitabine 7 Doxorubicin 6 Cyclophosphamide 5 Radiation 4 Nivolumab 4 Irinotecan 4 pembrolizumab 3 Zoledronic Acid 3 Vincristine 3 Temozolomide 3 Magnetic Resonance Spectroscopy 3 Ipilimumab 3 Docetaxel 3 Cisplatin 3 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3 pegfilgrastim 2 Tranexamic Acid 2 Trabectedin 2 Surveys and Questionnaires 2 Sunitinib 2 Standard of Care 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Observation 2 Methotrexate 2 Methods 2 Interviews as Topic 2 Injections 2 Indocyanine Green 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00538239 2015-02-13

SUCCEED

Merck Sharp & Dohme LLC

Phase 3 Completed

Bone Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡